echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Hesco will take $2.8 billion

    Hesco will take $2.8 billion

    • Last Update: 2021-02-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Pharmaceutical Network February 1st, January 29th, NMPA official website shows that Sichuan Haisco's Tegrelo tablets were approved and treated as reviews.
    addition, Hesco to imitate the 4 categories of the production of Enqu tatin Nofowe film into the administrative approval stage, is expected to be approved in recent days and as a review, sprint domestic third.
    2019 global sales of more than $2.8 billion as a drug used to treat AIDS.
    anti-thrombosis drug, is a direct action, reversible combination of P2Y12 plateplate inhibitors.
    is fast and powerful because it does not need to be metabolized and active in the liver.
    with the approval of Hesco's Grelo film, the product currently has 12 imitation companies in the domestic market.
    , which has previously been developed by AstraZeneta as AstraZeneta, will have global sales of more than $1.5 billion in 2019.
    2019, China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal sales of more than 1.5 billion yuan, according to data from china's inner network.
    entourtabinofovir tablets contain two active ingredients: entourtabin and fumarate nofovir difficide, both highly effective antiretroviral drugs.
    as a single tablet, enqutabinofovir tablets have the characteristics of simplified treatment, remarkable efficacy, high patient compliance with drug administration, low drug resistance and so on, for the national health insurance Class B drugs.
    Truvada Global Sales (millions of dollars) Source: Milnet Multinational Listed Companies Sales Database Entrutha Binte Nofovir Tablets, originally developed by Gilead's Truvada, was approved by the FDA in August 2004 for the treatment of HIV-1 infection in a joint antiretroviral drug, and in 2012 was approved by the FDA for adults with HIV-1 infection resulting from sexual transmission, the world's first HIV prevention drug.
    sales of more than $2.8 billion in 2019, according to the company.
    Enqutai Binte Nofowe tablets pending approval of enterprise sources: Mi net one-click search of the current domestic market Enqutha Binte Nofowe tablets approved enterprises have 3, including Gilead, Zhengda Tianqing Pharmaceutical Group and Anhui Baker Bio.
    Qilu Pharmaceuticals, Shanghai DiSano's Entourage Bintino Nofowe film listing application in the review and approval, Hesco's product registration status has been changed to "in the approval", if successfully approved will become the third domestic.
    source: Minet database
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.